The 12 New Drugs on the Horizon Presentation Titles for the AACR Annual Meeting 2026
Japan Approves Risovalisib For PIK3CA-Mutated Ovarian Clear Cell Carcinoma
Osimertinib Plus Chemotherapy Improves Outcomes in EGFR/TP53 mutant NSCLC: The TOP Study
Yvonne Awards 2026
The Mark Foundation Emerging Leader Award Winners Celebrate 8 Years of Transformational Program
Talha Badar: From Germline to Donor-Derived Mutations in MN
Thymic Health And Immunotherapy Outcomes In Patients With Cancer
Stephen V. Liu: Promising Results with Datopotamab Deruxtecan Combinations in NSCLC
